Ascletis' ASC36_35FDC Shows Stronger Weight Loss Than Rival Combos in Preclinical Data
Image
Hong Kong – – October 02, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) presented preclinical data showing its ASC36_35FDC injectable combination drove a 24.8% body-weight reduction in a diet-induced obesity rat model on Day 14, outperforming two competitor co-formulations tested under identical dosing conditions.
The data were unveiled in a short oral discussion at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, held September 28–October 2, 2026, in Milan, Italy.